Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case

World Journal of Surgical Oncology

Yung-Shun Juan³  Shu-Pin Huang³  Wen-Jeng Wu³  Jung-Tsung Shen⁵  Mei-Yu Jang⁵  Hung-Sheng Chen⁴  Yi-Ting Chen²  Ann-Shung Lieu⁷  Jih-Pin Lin¹  Tsung-Yi Huang⁶ 

[1] School of Post-baccalaureate Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;Department of Urology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;Department of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan;Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100 Tz-You 1st Road, Kaohsiung, Taiwan;Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

关键词: Prostate cancer;    Pituitary apoplexy;    Gonadotropin-releasing hormone agonists;   

Others  :  821503
DOI  :  10.1186/1477-7819-11-254

 received in 2013-07-17, accepted in 2013-09-19,  发布年份 2013

【 摘 要 】

We present the first Asian case of a 77-year-old man who developed pituitary apoplexy (PA) soon after gonadotropin-releasing hormone agonist (GnRHa) (leuprorelin) injection to treat prostate cancer. Headache, ophthalmoplegia, visual field deficit, nausea, and vomiting are the typical characteristics of pituitary apoplexy. Though the occurrence rate is rare, the consequence of this condition can vary from mild symptoms such as headache to life-threatening scenarios like conscious change. Magnetic resonance imaging is the best imaging modality to detect PA and sublabial trans-sphenoid pituitary tumor removal can resolve most of PA symptoms and is so far the best solution in consensus. We also review 11 previous reported cases receiving GnRHa for androgen deprivation therapy of prostate cancer, and hope to alert clinicians to use GnRHa with caution.

【 授权许可】

   
2013 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI, American Society of Clinical Oncology: American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004, 22:2927-2941.
• [2]Ando S, Hoshino T, Mihara S: Pituitary apoplexy after goserelin. Lancet 1995, 345:458.
• [3]Chanson P, Schaison G: Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma. J Clin Endocrinol Metab 1995, 80:2267-2268.
• [4]Morsi A, Jamal S, Silverberg JD: Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Clin Endocrinol 1996, 44:121-124.
• [5]Eaton HJ, Phillips PJ, Hanieh A, Cooper J, Bolt J, Torpy DJ: Rapid onset of pituitary apoplexy after goserelin implant for prostate cancer: need for heightened awareness. Int Med J 2001, 31:313-314.
• [6]Brougham M, Heusner AP, Adams RD: Acute degenerative changes in adenomas of the pituitary body-with special reference to pituitary apoplexy. J Neurosurg 1950, 7:421-439.
• [7]Davis A, Goel S, Picolos M, Wang M, Lavis V: Pituitary apoplexy after leuprolide. Pituitary 2006, 9:263-265.
• [8]Hands KE, Alvarez A, Bruder JM: Gonadotropin-releasing hormone agonist-induced pituitary apoplexy in treatment of prostate cancer: case report and review of literature. Endoc Prac 2007, 13:642-646.
• [9]Blaut K, Wisniewski P, Syrenicz A, Sworczak K: Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog. Neuro Endocrinol Lett 2006, 27:569-572.
• [10]Guerra Y, Lacuesta E, Marquez F, Raksin PB, Utset M, Fogelfeld L: Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary 2010, 13:54-59.
• [11]Engel G, Huston M, Oshima S, Beck C, Harsh G, Rosenthal MH, Camargo CA: Pituitary apoplexy after leuprolide injection for ovum donation. J Adolesc Health 2003, 32:89-93.
• [12]Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA: Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol 1999, 51:181-188.
• [13]Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A: Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer. Int J Urol 2006, 13:87-88.
• [14]Reznik Y, Chapon F, Lahlou N, Deboucher N, Mahoudeau J: Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer. J Endocrinol Invest 1997, 20:566-568.